A clinical trial to assess the effect on quality of life in post menoapausal osteoporotic women with salmon calcitonin nasal spray.

Assessment of Quality of life in postmenopausal women with osteoporosis using salmon calcitonin nasal spray.

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2010/091/002958

Enrollment

Registered

2010-11-16

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- postmenopausal osteoporosis

Interventions

Intervention1: Bonspark nasal spray ( salmon Calcitonin ): 200 IU calcitonin (salmon) per dose for 1 month Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: a. Postmenopausal women between 45-65 years of age or surgical menopausal (oophorectomy) cases b. Bone mineral density(BMD) values -2.5 SD in at least one region measured by Dual Energy X-ray absorptiometry (DEXA)

Exclusion criteria

Exclusion criteria: a. Presence of secondary causes of osteoporosis and other possible causes of back pain (fragility fracture ,bone metastasis or inflammatory spine disease such as spondylarthritis) b. Use of medications that cause osteoporosis c. Any contraindications for using salmon calcitonin or calcium d. History of taking anti osteoporotic agents in the last month

Design outcomes

Primary

Measure	Time frame
improvement in QOL and tolerabilityTimepoint: 1 month	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Amanjit Kaur Ahluwalia

Deputy General Manager- Medical Services

amanjita@glenmarkpharma.com9323328879

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026